1. Analyst View

2. Research Methodology

3. Immuno-Oncology: Overview

4. Market Dynamic

4.1 Drivers

4.1.1 Increasing Cancer Incidences

4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth

4.1.3 Growing Geriatric Population

4.1.4 High Healthcare Spending in Developed Economies

4.1.5 Strong Pipeline

4.1.6 Increasing Efficacy in a Wide Variety of Indications

4.1.7 urgeoning Approval and Uptake of Immuno-Oncology Products

4.2 Challenges

4.2.1 Patent Expiry of Top-Selling Drugs

4.2.2 Increasing Number of Side-Effects Post Immunotherapy Treatment

4.2.3 Sky-High Development Costs of Cancer Immunotherapies

4.2.4 High Cost of Treatment

4.2.5 Lack of Awarenes

4.3 Opportunities

4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunit

4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival

4.3.3 CAR-T Therapies: The Future of Cancer Care

4.3.4 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies

5. Global Immuno-Oncology Market Outlook 2022

6. Global Immuno-Oncology Market, by Product Class

6.1 Monoclonal Antibodies (mAbs)

6.1.1 Naked Monoclonal Antibodies

6.1.1.1 Rituxan (Rituximab)

6.1.1.2 Avastin (Bevacizumab)

6.1.1.3 Herceptin (Trastuzumab)

6.1.2 Conjugated Monoclonal Antibodies

6.1.2.1 ADCETRIS (Brentuximab vedotin)

6.1.2.2 Kadcyla (Ado-trastuzumab emtansine/TDM-1)

6.1.3 Bispecific Monoclonal Antibodies

6.1.3.1 Blincyto (Blinatumomab)

6.1.4 Others

6.2 Therapeutic Vaccines

6.2.1 Provenge

6.3 Immune Checkpoint Inhibitors

6.3.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)

6.3.1.1 Yervoy (Ipilimumab)

6.3.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand

6.3.2.1 Opdivo (Nivolumab)

6.3.2.2 Keytruda (Pembrolizumab)

6.4 Others

7. Global Immuno-Oncology Market, By Major Indications

7.1 Head & Neck Cancer

7.2 Lung Cancer

7.3 Melanoma

7.4 Lymphoma

7.5 Leukemia

7.6 Others 118

8. Global Immuno-Oncology Market, By Geography

8.1 North America

8.2 Europe

8.3 Asia-Pacific

9. Trends & Developments

9.1 Lucrative Investment Trend

9.2 Emergence of Targeted and Combination Therapies

9.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market

9.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers

10. Strategic Collaborations & Alliances in the Immuno-Oncology Industry

11. Pipeline Analysis of Immuno-Oncology

12. Competitive Landscape

12.1 Share of Major Players

13. Key Players Analysis

13.1 F. Hoffmann-La Roche AG

13.2 Celgene Corporation

13.3 Bristol-Myers Squibb

13.4 Merck & Co., Inc.

13.5 Novartis

13.6 AstraZeneca Plc

13.7 Pfizer Inc

13.8 Eli Lilly and Company

13.9 Johnson & Johnson

13.10 Amgen Inc.

List of Tables:

Table 4-1: Immuno-Oncology - Late Stage Research Pipeline

Table 4-2: US & Europe - Major Drug Patent Expiry in Immuno-Oncology Market

Table 6-1: Ongoing Trials for Rituxan

Table 6-2: Ongoing Trials for Avastin

Table 6-3: Ongoing Trials for Herceptin

Table 6-4: Ongoing Trials for ADCETRIS

Table 6-5: Ongoing Trials for Kadcyla

Table 6-6: Ongoing Trials for Blincyto

Table 6-7: Ongoing Trials for Other Monoclonal Antibodies

Table 6-8: Ongoing Trials for Provenge

Table 6-9: Ongoing Trials for Yervoy

Table 6-10: Ongoing Trials for Opdivo

Table 6-11: Ongoing Trials for Keytruda

Table 6-12: Ongoing Trials for Other Immuno-Oncology Products

Table 7-1: Global - Oncology Incidence by Geography (‘000), 2015 & 2020

Table 9-1: Immuno-Oncology Companies that Received Venture Capital Investments

Table 9-2: Selected Immuno-Oncology and/or Targeted Therapy Combinations

Table 10-1: Strategic Collaborations in the Immuno-Oncology Industry

Table 11-1: Active Immuno-Oncology Programs

Table 11-2: Global – Immuno-Oncology Product Pipeline

Table 13-1: F. Hoffmann-La Roche AG - Key Financials (Billion US$), 2014-2016

Table 13-2: F. Hoffmann-La Roche AG - Commercialized Immuno-Oncology Products

Table 13-3: F. Hoffmann-La Roche AG - Product Pipeline

Table 13-4: Celgene Corporation - Key Financials (Million US$), 2014-2016

Table 13-5: Celgene Corporation - Commercialized Immuno-Oncology Products

Table 13-6: Celgene Corporation - Product Pipeline

Table 13-7: Bristol Myers Squibb - Key Financials (Million US$), 2014-2016

Table 13-8: Bristol Myers Squibb - Commercialized Immuno-Oncology Products

Table 13-9: Bristol Myers Squibb - Product Pipeline

Table 13-10: Merck & Co., Inc. - Key Financials (Million US$), 2014-2016

Table 13-11: Merck & Co., Inc. - Commercialized Immuno-Oncology Products

Table 13-12: Merck & Co., Inc. - Product Pipeline

Table 13-13: Novartis - Key Financials (Billion US$), 2014-2016

Table 13-14: Novartis - Commercialized Immuno-Oncology Products

Table 13-15: Novartis - Product Pipeline

Table 13-16: AstraZeneca Plc - Key Financials (Million US$), 2014-2016

Table 13-17: AstraZeneca Plc - Commercialized Immuno-Oncology Products

Table 13-18: AstraZeneca Plc - Product Pipeline

Table 13-19: Pfizer Inc - Key Financials (Billion US$), 2014-2016

Table 13-20: Pfizer Inc - Commercialized Immuno-Oncology Products

Table 13-21: Pfizer Inc - Product Pipeline

Table 13-22: Eli Lilly and Company - Key Financials (Million US$), 2014-2016

Table 13-23: Eli Lilly and Company - Commercialized Immuno-Oncology Products

Table 13-24: Eli Lilly and Company - Product Pipeline

Table 13-25: Johnson & Johnson - Key Financials (Billion US$), 2014-2016

Table 13-26: Johnson & Johnson - Commercialized Immuno-Oncology Products

Table 13-27: Johnson & Johnson - Product Pipeline

Table 13-28: Amgen Inc. - Key Financials (Billion US$), 2014-2016

Table 13-29: Amgen Inc. - Commercialized Immuno-Oncology Products

Table 13-30: Amgen Inc. - Product Pipeline

List of Figures:

Figure 4-1: Global - Cancer Incidences (Million), 2015, 2020, 2025 & 2030

Figure 4-2: Global - Cancer Mortality (Million), 2015, 2020, 2025 & 2030

Figure 4-3: Global - Population above 60 Years (Billion), 2015 & 2050

Figure 4-4: Expected Combination Regimen Launches in Oncology

Figure 5-1: Global - Immuno-Oncology Market (Billion US$), 2016-2022

Figure 6-1: Global - Share of Immuno-Oncology Market by Product (%), 2016

Figure 6-2: Global - Share of Immuno-Oncology Market by Product (%), 2022

Figure 6-3: Global - Monoclonal Antibodies Market (Billion US$), 2016-2022

Figure 6-4: Global - Rituxan Market (Billion US$), 2012-2016

Figure 6-5: Global - Avastin Market (Billion US$), 2012-2016

Figure 6-6: Global - Herceptin Market (Billion US$), 2012-2016

Figure 6-7: Global - ADCETRIS Market (Million US$), 2012-2016

Figure 6-8: Global - Kadcyla Market (Million US$), 2013-2016

Figure 6-9: Global - Blincyto Market (Million US$), 2014-2016

Figure 6-10: Global - Other Monoclonal Antibodies Market (Billion US$), 2016-2022

Figure 6-11: Global - Therapeutic Cancer Vaccines Market (Billion US$), 2016-2022

Figure 6-12: Global - Provenge Market (Million US$), 2012-2016

Figure 6-13: Global - Immune Checkpoint Inhibitors Market (Billion US$), 2016-2022

Figure 6-14: Global - Yervoy Market (Million US$), 2012-2016

Figure 6-15: Global - Opdivo Market (Million US$), 2014-2016

Figure 6-16: Global - Keytruda Market (Million US$), 2014-2016

Figure 6-17: Global - Others Market (Billion US$), 2016-2022

Figure 7-1: Global - Share of Immuno-Oncology Market by Application (%), 2016

Figure 7-2: Global - Share of Immuno-Oncology Market by Application (%), 2022

Figure 7-3: Global - Head & Neck Cancer Market (Billion US$), 2016-2022

Figure 7-4: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-5: Head & Neck Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-6: Global - Lung Cancer Market (Billion US$), 2016-2022

Figure 7-7: Lung Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-8: Lung Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-9: Global - Melanoma Market (Billion US$), 2016-2022

Figure 7-10: Melanoma - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-11: Melanoma - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-12: Global - Lymphoma Market (Billion US$), 2016-2022

Figure 7-13: Lymphoma - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-14: Lymphoma - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-15: Global - Leukemia Market (Billion US$), 2016-2022

Figure 7-16: Leukemia - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-17: Leukemia - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 7-18: Global - Other Cancer Market (Billion US$), 2016-2022

Figure 7-19: Other Cancer - Immunotherapy Pipeline Analysis by Product (%), 2016

Figure 7-20: Other Cancer - Immunotherapy Pipeline Analysis by Phase (%), 2016

Figure 8-1: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2016

Figure 8-2: Global - Share of Immuno-Oncology Market by Geographic Regions (%), 2022

Figure 8-3: North America - Immuno-Oncology Market (Billion US$), 2016-2022

Figure 8-4: Europe - Immuno-Oncology Market (Billion US$), 2016-2022

Figure 8-5: Asia-Pacific - Immuno-Oncology Market (Billion US$), 2016-2022

Figure 9-1: Immuno-Oncology Funding by Product Type (Billion, US$), 2015-2016

Figure 9-2: Major Investors in Immuno-Oncology Market (2015-2016)

Figure 9-3: Bristol-Myers Squibb and Merck & Co. - Strategic Collaborations

Figure 11-1: Global - Immuno-Oncology Pipeline Analysis by Product Type (%), 2016

Figure 11-2: Global - Immuno-Oncology Pipeline Analysis by Phase (%), 2016

Figure 12-1: Global - Share of Key Players in Immuno-Oncology Market (%), 2015

Figure 13-1: F. Hoffmann-La Roche AG - Sales by Business Segments (%), 2016

Figure 13-2: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Segments (%), 2016

Figure 13-3: F. Hoffmann-La Roche AG - Pharmaceuticals Division Sales by Geography (%), 2016

Figure 13-4: Celgene Corporation - Sales by Products (%), 2016

Figure 13-5: Bristol Myers Squibb - Revenue by Business Segments (%), 2016

Figure 13-6: Bristol Myers Squibb - Revenue by Geography (%), 2016

Figure 13-7: Merck & Co., Inc. - Revenue by Business Segments (%), 2016

Figure 13-8: Merck & Co., Inc. - Pharmaceutical Division Revenue by Segments (%), 2016

Figure 13-9: Merck & Co., Inc. - Revenue by Geography (%), 2016

Figure 13-10: Novartis - Sales by Business Segments (%), 2016

Figure 13-11: Novartis - Innovative Medicines Division Sales by Segments (%), 2016

Figure 13-12: Novartis - Pharmaceuticals Division Sales by Segments (%), 2016

Figure 13-13: Novartis - Sales by Geography (%), 2016

Figure 13-14: AstraZeneca Plc - Revenue by Business Segments (%), 2016

Figure 13-15: AstraZeneca Plc - Revenue by Geography (%), 2016

Figure 13-16: Pfizer Inc - Revenue by Business Segments (%), 2016

Figure 13-17: Pfizer Inc - Revenue by Geography (%), 2016

Figure 13-18: Eli Lilly and Company - Revenue by Business Segments (%), 2016

Figure 13-19: Eli Lilly and Company - Human Pharmaceutical Division Revenue by Business Segments (%), 2016

Figure 13-20: Eli Lilly and Company - Revenue by Geography (%), 2016

Figure 13-21: Johnson & Johnson - Sales by Business Segments (%), 2016

Figure 13-22: Johnson & Johnson - Sales by Pharmaceutical Segments (%), 2016

Figure 13-23: Johnson & Johnson - Sales by Geography (%), 2016

Figure 13-24: Amgen Inc. - Sales by Product (%), 2016

Figure 13-25: Amgen Inc. - Sales by Geography (%), 2016